HCV蛋白酶抑制剂simeprevir与常用合并用药的药代动力学相互作用的临床影响
该事后汇总分析合并九项评估基于simeprevir的无干扰素HCV治疗研究,分析降压药、抗焦虑药和降脂药三类常用合并用药按DDI潜力分为琥珀色或绿色后的临床影响。复合主要终点为12周SMV治疗期间合并用药停药、中断或剂量调整的频率。琥珀色组合并用药调整频率(13.4-19.4%)高于绿色组(3.1-10.8%),不良事件频率无差异,提示已知或潜在PK相互作用可管理且调整少。
要点
- 琥珀色组合并用药调整频率13.4-19.4%,高于绿色组3.1-10.8%。
- 绿色与琥珀色组不良事件频率无差异。
- 与SMV已知或潜在PK相互作用的常用合并用药可管理,调整少。
核心结论
- 与SMV已知或潜在PK相互作用的常用合并用药可管理,合并用药调整少。
研究设计与样本
- 事后汇总分析合并九项评估基于simeprevir的无干扰素HCV治疗研究。
- 分析降压药、抗焦虑药和降脂药三类常用合并用药,按DDI潜力分为琥珀色或绿色。
- 复合主要终点为12周SMV治疗期间合并用药停药、中断或剂量调整的频率。
主要发现
- 各亚组中达到复合终点的患者少。
- 琥珀色组合并用药调整频率13.4-19.4%,绿色组3.1-10.8%。
- 绿色与琥珀色组不良事件频率无差异。
临床怎么用
- 对与SMV有已知或潜在PK相互作用的常用合并用药,可进行管理而无需频繁调整。
- 该方法可作为评估DDI影响的蓝图。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Direct-acting antiviral agents (DAAs) for the treatment of hepatitis C (HCV) can be associated with drug-drug interactions (DDIs) with concomitant medications. The practical clinical implications of such DDIs are poorly understood. We assessed the clinical impact of possible pharmacokinetic (PK) interactions between simeprevir and frequently prescribed concomitant medications. METHODS: This post hoc analysis pooled data from nine studies which evaluated simeprevir (SMV)-based interferon-free HCV treatment. Three classes of frequently used concomitant medications of interest (CMOIs) were analysed [antihypertensive drugs (AHDs), anxiolytic drugs (AXDs) and lipid-lowering drugs (LLDs)] and categorized as amber or green according to their DDI potential with SMV (green: no DDIs; amber: potential/known PK interactions). Concomitant medications not recommended to be coadministered with SMV were not included. The composite primary endpoint was defined as the frequency of either discontinuation, interruption or dose modification of the CMOI during 12 weeks of SMV treatment. RESULTS: Few patients met the composite endpoint in the various subgroups. Patients on amber CMOIs tended to experience CMOI modification more often (13.4-19.4%) than those on green CMOIs (3.1-10.8%). There was no difference in the frequency of adverse events between patients taking green and those taking amber CMOIs. CONCLUSIONS: In this large pooled analysis, coadministration of the evaluated commonly prescribed medications with known or potential PK interactions with SMV was manageable and resulted in few adjustments of concomitant medications. Our method could serve as a blueprint for the evaluation of the impact of DDIs.
引用
- Marra F, Höner Zu Siederdissen C, Khoo S, et al. Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications. Br J Clin Pharmacol. 2018. PMID: 29345798. doi:10.1111/bcp.13519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。